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Gorlin syndrome (Naevoid Basal Cell Carcinoma Syndrome) is a rare autosomal dominant syndrome caused by mutations in
the PTCH gene with a birth incidence of approximately 1 in 19,000. Patients develop multiple basal cell carcinomas of the skin
frequently in early life and also have a predisposition to additional malignancies such as medulloblastoma. Gorlin Syndrome
patients also have developmental defects such as biﬁd ribs and other complications such as jaw keratocysts. We studied the
incidence and frequency of basal cell carcinomas in 202 Gorlin syndrome patients from 62 families and compared this to their
gender and mutation type. Our data suggests that the incidence of basal cell carcinomas is equal between males and females and
the mutation type cannot be used to predict disease burden.
1.Introduction
Gorlin syndrome (also known as Naevoid Basal Cell Car-
cinoma Syndrome and Basal Cell Naevus Syndrome) is
characterised by the presence of a variety of developmental
anomalies and predisposition to a range of cancers. A major
and problematic feature of the disorder is the development
of multiple basal cell carcinomas (BCCs) which begin to
appear from the early teens. Other features of Gorlin
Syndrome include a recognizable facial appearance with
milia, macrocephaly, bossing of the forehead, hypertelorism,
a n dc o a r s ef a c i a lf e a t u r e sw h i c hi sp r e s e n ti n6 0 %o f
individuals with Gorlin Syndrome [1–3]. Examination of
the palms reveals the presence of pits in the palm of the
hand in most aﬀected individuals, which are characteristic.
Jaw keratocysts are common and often multiple and tend
to begin in the second decade of life. Skeletal anomalies
are also common and include biﬁd ribs, wedge-shaped
vertebrae, and a short 4th metacarpal. Ectopic calciﬁcation,
particularly in the falx, is present in more than 90% of
aﬀected individuals by age 20 years [3]. For reviews see
[1, 4].
In 1993 Evans et al. devised clinical criteria for making a
diagnosis of Gorlin Syndrome based on the most frequent
and/or speciﬁc features of the syndrome [3]. These have
since been modiﬁed in an attempt to improve diagnostic
accuracy[2, 4]. Table 1 details current diagnostic criteria and
a diagnosis can be made when 2 major or 1 major and 2
minor criteria are fulﬁlled.
Gorlin Syndrome is an autosomal dominant disorder
with an estimated birth incidence of 1 in 19,000 individuals
[5]. Penetrance is near complete [6] but there is extremely
variable expressivity. The development of BCCs is one of the
most problematic features of this disorder. The initial site of
appearance of BCCs is most frequently the face and nape of
the neck. The sites frequently involved are the face, back, and
chest and they are rarely found below waist. The median age
of onset is roughly 25 years but they may appear as early as
two years of age or as late as 65 years of age (authors personal
experience). BCCs can vary in number from only some to
thousands. There is a signiﬁcant tendency for proliferation
betweenpubertyand35years.BCCsinthissyndromebehave
in the same manner as sporadic BCCs and rarely metastasize.
The histology of the BCC is also similar to that of sporadic2 Journal of Skin Cancer
Table 1: Diagnostic criteria for Gorlin Syndrome. A diagnosis can be made when 2 major or 1 major and 2 minor criteria are fulﬁlled.
Major criteria Minor criteria
Lamellar (sheet-like) calciﬁcation of the falx or clear
evidence of calciﬁcation in an individual younger than
age of 20 years
Childhood medulloblastoma
Jaw keratocyst Lympho-mesenteric or pleural cysts
2 or more palmar/plantar pits Macrocephaly (OFC >97th centile)
Multiple BCCs (more than ﬁve in a lifetime) or a BCC
before age of 30 years. Cleft lip/palate
First degree relative with Gorlin Syndrome
Vertebral/rib anomalies such as biﬁd/splayed/extra ribs or biﬁd vertebrae
Preaxial or postaxial polydactyly
Ovarian/cardiac ﬁbromas
Ocular anomalies (cataract, developmental defects, and pigmentary
changes of the retinal epithelium)
BCCs and consists of nests and islands or sheets of large,
deeply stained nuclei with indistinct cell membranes [7].
The numbers of BCCs that develop have shown a
signiﬁcant association with skin pigmentation and sun
exposure; only 40% of African-American Gorlin syndrome
patients present BCCs with the number of lesions normally
less compared to the many BCCs in Caucasians. Shanley
et al. (1994) compared the phenotype of Australian Gorlin
Syndrome patients with those from the English survey by
Evans et al. [3] and found that multiple BCCs present from
an earlier age in the Australian population and postulated
that this maybe a sign of greater exposure to ultraviolet (UV)
radiation [8]. Radiation therapy triggers proliferation in the
BCCs [2] and can cause huge numbers to occur particularly
after radiotherapy in childhood [9].
Gorlin syndrome results from mutations in the PTCH
gene,thehumanhomologoftheDrosophilasegmentpolarity
gene patched (ptc)[ 10, 11]. It is interesting to note that
50% of sporadic BCCs have been found to have mutations in
thisgene[12].PTCH encodesatransmembraneglycoprotein
(made up of 1447 amino acids) with 12 transmembrane
domains and two extracellular loops, and a putative sterol
sensing domain. Alternative splicing results in multiple
transcript variants encoding diﬀerent isoforms. PTCH is
an integral component of the hedgehog signalling pathway,
which serves many developmental and regulatory roles.
AnalysisofPTCH mutationsinGorlinsyndromepatients
has identiﬁed deletions, insertions, splice site alterations,
nonsense, and missense mutations. There does not appear to
be a particular hot spot for mutations [13]. It is not known
if the mutation type correlates with the number of BCCs
thatdevelop.Approximately20%−30%ofprobandshaveade
novo mutation in PTCH, and some of these will be somatic
mosaics. Mosaicism is caused when a mutation arises early
in development. The resulting individual will be a mixture
of cells, some cells with the mutation and some cells without
themutation.Howearlyindevelopmentthemutationoccurs
will determine what tissue(s) and what percentage of cells
will have the mutation. If the mutation is not present in a
signiﬁcant proportion of blood cells, then the mutation will
not be detectable by routine mutation analysis.
The development of associated malignancies in Gorlin
Syndrome is thought to arise from the classic two-hit
suppressor gene model: baseline heterozygosity secondary to
germline PTCH mutation as the ﬁrst hit, with the second hit
due to mutagen exposure such as UV or ionizing radiation.
Loss of heterozygosity seems to also be the mechanism
for jaw cysts whereas congenital malformations may be
attributable to alterations in the concentration of the PTCH
gene product in the dosage sensitive hedgehog signalling
pathway [14].
We have assessed the presence, onset, and number of
BCCs in individuals with Gorlin syndrome and identiﬁed
whether presence or type of PTCH mutation or gender
impacts on this.
2. Methods
Identiﬁed cases of Gorlin Syndrome in the North West
Region were collected from the regional Gorlin Syndrome
Register(GeneticMedicine,StMary’sHospital,Manchester),
which was established in 1990 by DGE [3] as the result of
a study begun in 1982 by Dr P Farndon. All individuals
on the register have been found to have a mutation in
the PTCH gene or meet clinical criteria for a diagnosis of
Gorlin Syndrome. In the current study, 202 patients from 62
families were ascertained from the Gorlin Syndrome register.
The clinical details for each patient were recorded from the
hospital notes. SPSS and MedCalc were used for data anal-
ysis, and Kaplan-Meier curves were drawn. Mutation types
were deﬁned as (1) truncating mutation (small frameshift
deletionsorinsertionsornonsensemutations),(2)splicesite
donororacceptor;(3)missensemutations;(4)largesingleor
multiexon deletions.
3. Results
There were 202 conﬁrmed cases of Gorlin Syndrome on the
register database, which included 100 females and 102 males.
All bar one individual/family was of white European origin
with the only exception of Indo-Asian descent. 158 patientsJournal of Skin Cancer 3
had been tested for mutations in PTCH, and mutations
have been identiﬁed in 96 (61%). Untested aﬀected family
members were assumed to have the same result as a tested
proband. BCCs had been diagnosed in 135/202 (67%) of
Gorlin Syndrome patients. Similar proportions of males
(64%) and females (70%) had been diagnosed with a BCC.
67 individuals had not had a BCC. Only four individuals
with Gorlin Syndrome and aged greater than 50 years had no
BCCs, and the majority without BCCs were <40 years of age
(44/67) with nearly half (30/67) being <20 years of age. Five
individuals with PTCH mutations did not have a diagnosed
BCC after 40 years of age.
We ﬁrst studied the incidence of BCCs in males and
females in our cohort. Figure 1 shows Kaplan-Meier curves
of cumulative incidence of BCCs with age comparing male
patients and female patients. Both curves rise in a similar
manner and are close together. The curves (and data) show
that the cumulative incidence of BCCs at age 20 years in
male patients is 13.7% and 12% in female patients. By 50
years of age, 76.5% of females and 80% of males had been
diagnosed with a BCC. A long rank test was performed
assuming similarity in the curves, and this produced a P-
value of .625 with a Hazard ratio of 0.92 for females against
males. These results show that male Gorlin patients do not
have a higher cumulative incidence of BCCs with age than
female patients.
We next divided our cohort of patients into 3 groups:
those with a known mutation, those in whom no mutation
had been identiﬁed, and those in whom the mutation
status was unknown. Figure 2 shows Kaplan-Meier curves of
cumulative incidence of BCCs with age comparing patients
with (1) patients with an identiﬁed PTCH mutation; (2)
patients in whom the mutation status is unknown; (3)
patients in whom no mutation was found. All three curves
rise in a similar manner and are again very closely aligned.
The curves (and data) show that the cumulative incidence
of BCCs at age 20 years in patients with a mutation is 12%,
3% in those with an unknown status, and 12% in those in
whom a mutation was not found. At 30 years the cumulative
incidence of BCCs in patients with a mutation is 34.5%,
32% in those with an unknown status, and about 34.5%
in those in whom a mutation was not found. A long rank
test was performed assuming similarity in the curves, and
this produced a P-value of .616. These results show that
patients with a PTCH mutation (i.e., those with deﬁnite
Gorlin syndrome) do not have a higher cumulative incidence
of BCCs with age than those in whom a mutation was not
found and in those whom the mutation status is unknown.
Therefore, it does not appear that individuals who may be
somatic mosaics for a PTCH mutation but fulﬁll diagnostic
criteria or whose Gorlin syndrome could be caused by an as
yet unidentiﬁed gene have a lower BCC load.
We next assessed if type of mutation aﬀected incidence
of BCC. Ninety-four individuals with identiﬁed mutations
were assessable for BCC incidence (truncating mutation n =
38, splice-site mutation n = 15, large single or multiexon
deletion n = 15, and missense mutation n = 26). Figure 3
shows Kaplan-Meier curves of cumulative incidence of BCCs
with age comparing patients with three mutation types. All
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Figure 2:CumulativeonsetofBCCbypresenceofPTCH mutation.
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Figure 3: Cumulative onset of BCCs by type of PTCH mutation.
Missense (mis) n = 26. Splicing (spl) n = 15. Truncating (tru) n =
38.
three curves rise in a similar manner and are closely aligned;
the large deletion curve is shown as part of Figure 4.T h e
curves (and data) show that the cumulative incidence of
BCCs at age 30 years in patients with a truncating mutation
is 29%, 29% in those with a splice-site mutation, and
32% in those with a missense mutation. A long rank test
was performed assuming similarity in the curves, and this
produced a P-value of .38. These results show that patients
with a truncating mutation do not have a higher cumulative
incidence of BCCs with age than those with a splice-site
mutation or missense mutation. This suggests that missense
mutations are not associated with a milder form of Gorlin
syndrome than truncating or splice-site mutations.
Finally, the eﬀect of mutation position was assessed. The
PTCH gene was divided into two portions, exons 1-11 and
exons 12-18. Whole gene deletions were treated as a separate
group. Figure 4 again shows no signiﬁcant diﬀerence in BCC
onset dependant on mutation position (P = .617).
4. Discussion
Gorlin syndrome is characterized by the presence of multiple
BCCs, yet little is known about whether gender or mutation
type inﬂuences the age at onset and number of tumours
that develop. Gorlin syndrome is known to be the result of
mutations in the PTCH gene. The mutation detection rate is
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Figure 4: Eﬀect of mutation position on onset of BCCs.
lowat61%intheManchesterseriesbutthisissimilartomost
other reports in Gorlin Syndrome [15–18]. Some of this can
be explained by somatic mosaics in who the mutation is not
detectable in blood. Mutation analysis has not been carried
out in a systematic way, and this may also contribute to the
low detection rate.
To date, no ﬁrm evidence for a genotype/phenotype
correlation in Gorlin syndrome has been demonstrated,
and there is adequate variation in single families to believe
that environmental exposure and perhaps modiﬁer genes
may justify much of the variation. We have shown that
presence or absence of a PTCH mutation, mutation type,
and gender have virtually no impact on the age at which the
ﬁrst BCCs develop or the numbers of BCCs that develop.
This is clinically relevant as the ﬁnding of a speciﬁc PTCH
mutation does not appear to give prognostic information
about the likely age of onset of BCC or the clinical disease
burden.
Mutation position and type of mutation have been
shown to aﬀect phenotype for a number of tumour-prone
disorders including neuroﬁbromatosis type 2 (NF2) [19,
20] and familial adenomatous polyposis [21]. Although the
numbers with detected mutations are relatively small, they
should be large enough to detect a potential hypomorphic
eﬀectofmissensemutationsinPTCH inourstudyorasevere
eﬀect of truncating mutations as seen in NF2.Journal of Skin Cancer 5
It is interesting to note that biallelic loss of PTCH in
adult conditional PTCH-knockout mice developed tumours
of the skin on the tails and ears. These tumours had features
of human nodular BCCs. The inactivation of PTCH at
diﬀerent timepoints in this mouse model predisposed to
the development of diﬀerent tumour types. For example,
rhabdomyosarcoma results from the prenatal inactivation of
PTCH whereas BCC do not. This study demonstrates that
the time point and mode of inactivation of the second allele
aﬀect the spectrum of associated tumours and may explain
some of the clinical variation seen in this disorder [22].
A major problem for Gorlin patients is the sheer number
of BCCs which can develop. Only a small fraction of
these become invasive but they can invade deep underly-
ing structures, especially in the face. Diﬀerent treatment
modalities are used in these patients: surgical excision, Mohs
micrographic surgery, cryotherapy, photodynamic therapy,
ablative laser therapy, and topical 5% imiquimod [4]. Trials
are also underway investigating the role of speciﬁc hedgehog
pathway inhibitors in treatment. It will be interesting to see if
mutationpositivepatientsresponddiﬀerentlytotheseagents
than mutation negative patients.
5. Conclusion
In Gorlin Syndrome patients, neither the age of onset of
BCCs or the numbers of BCCs that develop can be predicted
by the presence or absence of a PTCH mutation or by
mutation type. Males and females appear to be equally
aﬀected by BCCs.
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